DADC
TENX icon

D.A. Davidson & Co’s Tenax Therapeutics TENX Stock Holding History

D.A. Davidson & Co’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1
Closed -$12K – 1897
2017
Q2 		$12K Hold
1
– – ﹤0.01% 1987
2017
Q1 		$11K Buy
+1
New +$36.3K ﹤0.01% 2005
2016
Q4 		– Hold
0
– – – 1802

Other funds holding TENX

FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

D.A. Davidson & Co's TENX Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Tenax Therapeutics (TENX) in Q3 2017, closing a stake of 1 share — an estimated $12K sold.

D.A. Davidson & Co first reported a position in TENX in Q1 2017 and held it in 2 quarters. The position peaked at $12K in Q2 2017. 11 funds tracked by Wall St. Rank hold TENX as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Tenax Therapeutics position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 1 Tenax Therapeutics share in Q3 2017, an estimated $12K.
  • D.A. Davidson & Co first reported a position in Tenax Therapeutics in Q1 2017 and held it in 2 quarters.
  • D.A. Davidson & Co's Tenax Therapeutics position peaked at $12K in Q2 2017.
  • 11 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.